Results PCOS among females with semaglutide and tirzepatide prescriptions Between 2021 and 2025, 1,738,008 female patients received a prescription for semaglutide or tirzepatide
The incidence of any DR was 15.6 (95% confidence interval [CI], 14.3 to 16.8) events per 1,000 person-years in SGLT2i group and 19.3 (95% CI, 17.3 to 21.3) events per 1,000 person-years in GLP1-RA group, and the rate of any DR (subdistribution hazard ratio [SHR], 0.90
Unlike a one-size-fits-all model, we adapt treatments as needed, monitoring progress closely
Benefits of Semaglutide after pregnancy Many women experience slower metabolisms after pregnancy, hormonal shifts, and challenges with weight management
Understanding these potential risks allows patients and healthcare professionals to proactively address oral health concerns, ensuring the benefits of Ozempic are not overshadowed by preventable dental problems
If you would like to find out if GLP-1 medications could help you, contact Swedish Weight Loss Services